News

The incredible research done here in Oxford is consistently making front page news across the world. Please see some of the highlights of our excellent work below.

From bench to bedside in two years: collaborative science opens the way for a new drug for bowel cancer patients across the UK

Today a new drug will become available for patients with bowel cancer as part of a national clinical trial; based on a scientific discovery made only two years ago at the University of Oxford.

Researchers Make Breakthrough Discovery in Fight against Colorectal Cancer

Professor Tim Maughan, Professor of Clinical Oncology at the University of Oxford and Principal Lead of the S:CORT Consortium said: “This research emphasises how a collaborative approach can give significant insight into bowel cancer disease biology, but also to begin to translate this knowledge into clinically-relevant applications. As part of the work of the S:CORT consortium, we will now focus on making sure that the research is put into practice so that it can become part of the standard of care for patients.”

FOXFIRE Combined Analysis Update

FOXFIRE Combined Analysis indicates no benefit in overall survival from adding selective internal radiotherapy [SIRT] to first-line oxaliplatin-based chemotherapy for metastatic colorectal cancer. Secondary analyses confirm improved control of liver metastases with liver-directed SIRT and show clinical benefit in patients with liver metastases originating from difficult-to-treat right-sided colon cancer.

New Era in Precision Medicine for Pancreatic Cancer

The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK today.
Preclinical validation lab

Radiotherapy risks are much higher for smokers

Smokers treated for breast cancer have much higher risks than non-smokers of developing lung cancer or heart attack as a result of radiotherapy – according to a new study lead by the University of Oxford published in the Journal of Clinical Oncology.

2017 Symposium Registration - Open now!

The day will be a celebration of the wealth of excellence we have here in Oxford, and the passion and commitment to cancer research that is shared across our community. The 2017 symposium will focus on the themes of Prevent, Detect & Cure, and feature multidisciplinary speakers from across the University and Oxford University Hospitals NHS Foundation Trust. Register today!
,

CRUK Science Blog: Training viruses to be cancer killers

For decades, scientists and doctors have looked for ways to stop the damage that viruses cause to humans. But in recent years, certain safe, modified viruses have emerged as potential allies to tackle cancer. Professor Len Seymour’s lab, at the Cancer Research UK Oxford Centre, has been focusing on one particular cancer-killing virus that operates under the code name of Enadenotucirev (or EnAd for short). Find out more in the CRUK Science Blog here.
,

Gold nanoparticles help deliver lethal one-two punch to cancer

Tagging gold nanoparticles with a small dose of radiation has helped researchers trace the precious metal as it delivers a drug right into the heart of cancer cells, according to new laboratory research being presented at the 2016 National Cancer Research Institute (NCRI) Cancer conference.

Oxford is Standing Up to Cancer!

Cancer Research UK Oxford Centre members from the Department of Oncology and Institute of Biomedical Engineering – Professor Boris Vojnovic, Professor Anne Kiltie, Jia-Ling Ruan, Yesna Yildiz and Professor Eleanor Stride,will all be part of the Stand Up to Cancer audience tonight!
,

Monitoring prostate cancer offers the same survival chance as surgery or radiotherapy over 10 years, but treatment reduces risk of cancer progression

Active monitoring is as effective as surgery and radiotherapy, in terms of survival at 10 years, reports the largest study of its kind, funded by the National Institute for Health Research (NIHR).
,

Oxford researcher awarded nearly £1m to explore potentially 'game-changing' treatments for prostate cancer

Dr Richard Bryant, a consultant urologist and surgeon who treats patients from across Oxfordshire, has been awarded almost £1m from Cancer Research UK to investigate a new form of treatment for prostate cancer
Themes
, ,

Anti-malaria drug could make tumours easier to treat

An anti-malaria drug could help radiotherapy destroy tumours according to a Cancer Research UK-funded study in Oxford, published in Nature Communications.